Press release
Alzheimer's Disease Treatment Market Size, Share, Statistics, Trends, Competitive analysis, Regional Growth from 2022 to 2030
North America takes a strong lead in the Alzheimer's disease treatment market. Factors responsible for the growth of regional market involves high prevalence of the disease, with rising cases resulting in spreading awareness of early diagnosis of the disease, accelerated demand for advanced therapies and diagnostic tool with modified drugs are the factors that contribute to its fullest for the North American regional growth of Alzheimer's disease treatment market.
On the other hand, Asia Pacific regional market will grow stupendously in the coming years by recording the largest CAGR for the Alzheimer's disease treatment market. Notable improvements in healthcare infrastructure and surge in awareness regarding early detection of the disease followed by the treatment options bolster the regional market growth in Asia Pacific region. Government through collaborations is better performing for Alzheimer's disease fuel the regional market growth.
DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2554
Department of Science & Technology (DST) through Cognitive Science Research Initiative (CSRI) is working together for the development of the better solution for mental disorders like Alzheimer & Dementia for determining early detection methods, psychological interventions, better therapies, and rehabilitation programs.
Market Dynamics
Rising prevalence of Alzheimer's disease is the prominent factor that boosts the overall market growth
According to Bright focus Foundation, globally at least 50 million people are living with Alzheimer's disease or other dementia disorders. According to the United Nations, Alzheimer's disease is more prevalent than its population. The estimates show that rates could exceed 152 million by 2050. Further statistics show that between 2000 to 2016 deaths attributed to Alzheimer's disease increased by 139% while those attributed to the number one cause of death-heart disease decreased by 6%. This increased statistics reflect changes in patterns of reporting deaths on death certificates over time as well as increase in the actual number of deaths caused by Alzheimer's.
VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/alzheimers-disease-treatment-market
Segmental Analysis
Alzheimer's disease treatment market is segmented based on drug class and distribution channel.
By drug class, the market is segmented based on cholinergic, memantine, combined drug, AChE inhibitors, and immunoglobulins. Based on distribution channel, the market is segmented as hospital pharmacy, retail pharmacy, and online sales.
By drug class, cholinergic drugs will record significant market share in the coming years due to prominent pharmacological actions like delaying loss of mental abilities for people suffering from mild to moderate Alzheimer's disease. Based on distribution channel, hospital pharmacy is recording significant segmental growth from the past and will continue the trend of dominance in the coming years.
Some of the leading competitors are Allergan, Eisai Co., Ltd., Novartis AG, DAIICHI SANKYO COMPANY, LIMITED., Merz Pharma, Pfizer Inc., Johnson & Johnson Services, Inc., H. Lundbeck A/S, Biogen, AstraZeneca, F. Hoffmann-La Roche Ltd, VTV Therapeutics, TauRx, Eli Lilly and Company., Teva Pharmaceutical Industries Ltd., ONO PHARMACEUTICAL CO., LTD., AC Immune, AB Science, AbbVie Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Bayer AG, and among others.
Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports
Some of the key observations regarding the Alzheimer's disease Treatment industry include:
• In January 2020, Biogen announced the acquisition of a novel clinical stage asset with application in Alzheimer's disease and Parkinson's disease from Pfizer, Inc. Biogen plans to develop a phase 1 asset for the treatment of sundowning in Alzheimer's disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson's disease.
• In July 2020, UCB announced a collaboration with F. Hoffmann-La Roche Ltd. for developing antibody treatment for people living with Alzheimer's disease. The collaboration enhance more research, patient centric development approach, and leading experience in neurological diseases offering holistic view towards the unmet needs and potential for an effective anti-Tau antibody for the treatment of neurodegenerative disease like Alzheimer's disease.
• In November 2019, Green Valley announced the approval of Oligomannate for mild to moderate Alzheimer's disease. It is considered a novel drug that is approved for Alzheimer's disease globally. This new product approval will provide a new treatment option to fight Alzheimer's disease for patients and is already available for sale in China since 2019.
INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2554
BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2554
201, Vaidehi-Saaket, Baner - Pashan Link Rd, Pashan, Pune, Maharashtra 411021
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Treatment Market Size, Share, Statistics, Trends, Competitive analysis, Regional Growth from 2022 to 2030 here
News-ID: 2852737 • Views: …
More Releases from Acumen Research and Consulting
Semiconductor Packaging Market to Double from USD 44.21 Billion in 2024 to USD 1 …
Acumen Research And Consulting announces the release of its latest industry report highlighting the robust growth of the Semiconductor Packaging Market. The report reveals that the global market, valued at USD 44.21 billion in 2024, is projected to reach USD 104.76 billion by 2033, expanding at a steady Compound Annual Growth Rate (CAGR) of 10.1% between 2025 and 2033. This rapid growth underscores the increasing importance of packaging innovations in…
Global Dual Chamber Prefilled Syringes Market to Reach USD 323.7 Million by 2032 …
According to the latest report by Acumen Research and Consulting, the global Dual Chamber Prefilled Syringes Market is witnessing rapid expansion, driven by rising adoption of advanced drug delivery systems, increasing demand for biologics, and the growing emphasis on patient safety and convenience.
The Dual Chamber Prefilled Syringes Market Size was valued at USD 162.2 million in 2023 and is projected to reach USD 323.7 million by 2032, growing at a…
Autonomous Data Platform Market to Reach USD 11.62 Billion by 2033, Growing at a …
The global Autonomous Data Platform Market is experiencing significant growth, driven by the increasing demand for AI-driven data management and real-time analytics across various industries. According to a comprehensive market analysis by Acumen Research and Consulting, the market was valued at USD 1.85 billion in 2024 and is projected to reach USD 11.62 billion by 2033, expanding at a robust compound annual growth rate (CAGR) of 22.9% during the forecast…
Compact High Pressure Laminates Market to Reach USD 9.6 Billion by 2032, Driven …
The Compact High Pressure Laminates Market is gaining remarkable momentum as industries across construction, interior design, healthcare, and commercial applications increasingly adopt durable, stylish, and sustainable surfacing solutions. Valued at USD 5.9 Billion in 2023, the market is projected to reach USD 9.6 Billion by 2032, reflecting a steady compound annual growth rate (CAGR) of 5.6%.
Get Free PDF Sample Pages of This Report: https://www.acumenresearchandconsulting.com/request-sample/3646
Compact High Pressure Laminates, or Compact HPL,…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
